Health ❯ Pharmaceuticals ❯ Biotechnology

Clinical Trials

Vaccine Development Drug Delivery Drug Development Nanobodies

Lead-Plaintiff Deadline Nears in MoonLake Securities Suits After SLK Trial Miss

Complaints allege the company overstated sonelokimab’s superiority, leading to an 89.9% stock collapse after Phase 3 results.

MoonLake Investors Courted by Law Firms as Lead‑Plaintiff Deadline Nears in SDNY Securities Case

Eupraxia Selects 8 mg Dose After Strong EoE Signals, Expands Phase 2b Trial